Phrontline Biopharma is dedicated to developing innovative antibody-drug conjugates (ADCs) to address unmet medical needs in oncology. We specialize in engineering dual-targeting antibodies to enhance the precision and efficiency of payload delivery. In parallel, our proprietary dual-payload platforms are designed to overcome drug resistance and extend treatment response, inspired by the clinical success of combination chemotherapy. Guided by science and driven by innovation, Phrontline is committed to becoming a leading global biopharmaceutical company focused on delivering next-generation frontline cancer therapies.